Cancer: New Jackson Lab Mice Could Expedite Immune-Oncological Research In Vivo
The Jackson Laboratory, one of the nation’s leading biomedical research facilities involved in mammalian genetics and cancer research, has developed a new strain of mice that have the power to accelerate immune-oncological and infectious diseases studies.
Humanized NSG-SGM3 transgenic mice, were bred to allow for the rapid development of human CD4+ T lymphocytes and other myeloid cells in vivo after human cell transplants. The mice originated from the same genetic lineage as The Jackson Laboratory’s already popular NSG mice that express essential human immune cytokines and hematopoietic cell growth factors.
Expression of immune cells in mice models enables researchers to have more accurate pictures of human immune responses against tumors in non-human clinical trials. One particular target of study is the PD-L1 inhibitory receptor, which in normal humans will regulate and inhibit immune responses to keep the body’s reactions to foreign antigens in check. In The Jackson Laboratory’s Onco-Hu models, NSG-SGM3 mice are grafted with human cells that express the PD-L1 receptor proteins, and provide a mechanism to study the effects of turning off the immune “checkpoint” on anti-tumor activity. In theory, inhibition of PD-L1 will allow for enhancement of the body’s own immune responses against tumor cells, and prevent future growth without the harmful side effects of radiation and chemotherapy.
To read more, click here.